ArticlePharmaceuticals (Basel, Switzerland)2020
Later-Line Treatment with Lorlatinib in
Open access · goldAbstract read
In one paragraph
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.Future oncology (London, England) · 2025Trial
- Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel.Future oncology (London, England) · 2026Review
- Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia.Exploration of targeted anti-tumor therapy · 2026Article
- Crizotinib in Patients WithJTO clinical and research reports · 2025Article
- The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients.Molecular oncology · 2025Article
- Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.BMC cancer · 2025Article
- Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cancers · 2024Article
- A descriptive analysis of real-world oncology biosimilar use in Japan.Future oncology (London, England) · 2024Observational
- Real world study of safety and efficacy of lorlatinib as second line and beyond inEcancermedicalscience · 2024Article
- From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).Diagnostics (Basel, Switzerland) · 2023Review
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Current oncology (Toronto, Ont.) · 2023Article
- Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.Cancer science · 2023Observational
- Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.Current oncology (Toronto, Ont.) · 2022Article
- Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.Thoracic cancer · 2022Article
- Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.ESMO open · 2022Article
- Article
- Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Maximilian J HochmairDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.ORCID 0000-0002-8673-2450
Hannah FabikanDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.
Oliver IlliniDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.ORCID 0000-0002-7322-7092
Christoph WeinlingerDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.
Ulrike SetinekInstitute of Pathology and Clinical Microbiology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria.
Dagmar KrenbekInstitute of Pathology and Clinical Microbiology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria.
Helmut ProschDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Währingergürtel 18-22, 1090 Vienna, Austria.
Markus RauterClinic of Pneumology, Klinikum Klagenfurt am Wörthersee, Feschnigstrasse 11, 9020 Klagenfurt am Wörthersee, Austria.
Michael SchumacherOrdensklinikum Linz Elisabethinen, Fadingerstrasse 1, 4020 Linz, Austria.
Ewald WöllSt. Vinzenz Krankenhaus Betriebs GmbH, Klostergasse 10, 6511 Zams, Austria.
Romana WassDepartment of Pneumology, Johannes Kepler University Linz, Krankenhausstrasse 26-30/Med Campus IV, 4020 Linz, Austria.
Elmar BrehmDepartment of Pneumology, Johannes Kepler University Linz, Krankenhausstrasse 26-30/Med Campus IV, 4020 Linz, Austria.
Gudrun AbsengerDepartment of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Tatjana BundaloLandesklinikum Hochegg, Hocheggerstrasse 88, 2840 Hochegg, Austria.
Peter ErrhaltClinical Department of Pneumology, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria.
Matthias UrbanDepartment of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.
Arschang ValipourDepartment of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Brünner Strasse 68, 1210 Vienna, Austria.
Johannes Kepler University of Linz · ATWilhelminen Hospital · ATKlinikum Klagenfurt · ATKrankenhaus der Elisabethinen · ATMedical University of Graz · ATMedical University of Vienna · ATUniversitätsklinikum Krems · AT
Funding
No grant is acknowledged in the PubMed record.
Abstract
In clinical practice, patients with
Indexed as
ALK-positive diseaseALK tyrosine kinase inhibitor treatmentlorlatinibROS1-positive diseasesequential treatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.